Please login to the form below

Not currently logged in
Email:
Password:

Zentiva

This page shows the latest Zentiva news and features for those working in and with pharma, biotech and healthcare.

Sanofi warns of difficult few months as diabetes sales slump

Sanofi warns of difficult few months as diabetes sales slump

said that the last few months have included the pipeline-building acquisitions of Bioverativ and Ablynx and the sale of its Zentiva generics business to a private equity group.

Latest news

  • Sanofi appoints ex-Roche Reed as new R&D head Sanofi appoints ex-Roche Reed as new R&D head

    Brandicourt has also demonstrated his commitment to pursuing the core pharma business at Sanofi by selling off its Zentiva generics business for 1.9bn ($2.4bn).

  • Sanofi sells European generics to Advent for $2.4bn Sanofi sells European generics to Advent for $2.4bn

    Sanofi has been looking to divest the Zentiva generics unit since 2016 as part of restructuring the business under chief executive Olivier Brandicourt, who said: “Transferring this business to Advent is ... Sanofi bought the foundations of its European

  • Ten new medicines recommended in Europe Ten new medicines recommended in Europe

    Duloxetine Zentiva (duloxetine) - a copycat of Lilly's Cymbalta - for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder, also saw a nod from the EMA.

  • Three cancer immunotherapies amongst new CHMP approvals Three cancer immunotherapies amongst new CHMP approvals

    Finally, two generic medicines gained positive opinions: Bortezomib Accord (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma and Pregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    Completing the positive opinions were two new informed consent applications: Sevelamer carbonate Zentiva (sevelamer) from Genzyme for the control of hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis and Rasagiline

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics